



FOR IMMEDIATE RELEASE

## More than 200 Companies Select Veeva Vault RIM Applications to Streamline Regulatory Operations

*Organizations are leveraging Vault RIM to keep pace with changing regulations*

**PLEASANTON, CA — February 6, 2020 — Veeva Systems** (NYSE:VEEV) today announced an increasing number of life sciences companies are adopting applications in the **Veeva Vault RIM Suite** to streamline regulatory information management. More than 200 companies are now using Vault RIM applications to modernize their regulatory business operations for faster submission development and better visibility across processes for improved compliance.

“It is critical to have the right processes and systems in place to leverage regulatory information freely across functions and borders,” said Regina Freunsch, vice president and global head of regulatory operations at Merck Healthcare KGaA, Darmstadt, Germany. “Veeva Vault RIM gives us a modern cloud application to streamline submissions and improve visibility into global regulatory processes.”

Vault RIM brings together regulatory content and data to give life sciences companies of all sizes one authoritative source for product registration information, submission documents, published dossiers, and health authority interactions. Companies can automate workflows to get the right documents to the right people for approval, eliminating the need for multiple systems and manual tracking spreadsheets that slow execution and increase compliance risk.

Veeva continues to deliver new innovations in Veeva Vault that improve how teams work together. Veeva Vault’s new **collaborative authoring with Microsoft Office** enables multiple users to simultaneously author and edit documents in Microsoft Office desktop applications directly from Veeva Vault. Now regulatory teams can seamlessly collaborate on submission documents for improved control and productivity.

“Global markets and continuously evolving regulations such as IDMP increase complexity and introduce greater challenges for regulatory teams preparing and reviewing submissions,” said John Lawrie, vice president, Veeva Vault RIM. “Veeva is committed to delivering continued innovation that helps the industry streamline regulatory information management and adapt to new regulatory data standards so customers have more flexibility to keep pace with changing regulations.”

The Veeva Vault RIM Suite includes **Vault Registrations**, **Vault Submissions**, **Vault Submissions Publishing**, and **Vault Submissions Archive** for fully integrated RIM capabilities on a single cloud platform. Vault RIM is part of **Veeva Development Cloud**, a unified suite of applications for clinical, regulatory, quality, and safety to help organizations drive end-to-end business processes across R&D and manufacturing.

Join Veeva, Viela Bio, Radius Health, and Alexion Pharmaceuticals at **DIA RSIDM Forum** on Feb. 11, from 4:15 p.m. – 5:30 p.m., to learn more about how life sciences companies are streamlining regulatory processes and accelerating end-to-end submission development.

### Additional Information

For more on Veeva Vault RIM Suite, visit: [veeva.com/RIM](https://veeva.com/RIM)

Connect with Veeva on LinkedIn: [linkedin.com/company/veeva-systems](https://linkedin.com/company/veeva-systems)

Follow @veevasystems on Twitter: [twitter.com/veevasystems](https://twitter.com/veevasystems)

Like Veeva on Facebook: [facebook.com/veevasystems](https://facebook.com/veevasystems)

### About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 800 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva

is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit [veeva.com](http://veeva.com).

### **Forward-looking Statements**

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended October 31, 2019. This is available on the company's website at [veeva.com](http://veeva.com) under the Investors section and on the SEC's website at [sec.gov](http://sec.gov). Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

###

### **Contact:**

Roger Villareal  
Veeva Systems  
925-264-8885  
[roger.villareal@veeva.com](mailto:roger.villareal@veeva.com)

Deivis Mercado  
Veeva Systems  
925-226-8821  
[deivis.mercado@veeva.com](mailto:deivis.mercado@veeva.com)